Join our email list to stay up to date on the latest Amyloidosis news.

Two vitally important reviews are underway for patisiran and inotersen, new treatments that have been trialed for hATTR patients.

One review is led by the National Institute for Health and Clinical Excellence (NICE) in the UK. (more…)

*

*

*

*